"There's a bit of a misperception that the exits are not as large. There's also a little bit of a misperception that corporate buyers in the medtech space aren't going to come in very early, they're not going to pay too much, and then you're going to struggle to get reimbursement." – Kyparissia Sirinakis, managing partner, Epidarex Capital
> Find out more: Harpoon Finds Its Whale: Edwards Spends Up To $250m For Beating-Heart Mitral Repair Option
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?